Clinical perspectives on dosimetry in molecular radiotherapy

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Molecular radiotherapy utilizes systemically administered unsealed radioactive sources for cancer treatment.
• Theragnostics involves paired radiopharmaceuticals for imaging and therapy targeting specific sites.
• Historically, molecular radiotherapy has relied on empirical, standardized activity schedules without precise dose estimation.

Purpose of the Study:

• To highlight the limitations of empirical dosing in molecular radiotherapy.
• To advocate for personalized treatment planning through accurate dosimetry in molecular radiotherapy.
• To emphasize the potential of theragnostic imaging for optimizing radiation absorbed doses in tumors and organs at risk.

Main Methods:

• Discussion of the current empirical approach to molecular radiotherapy administration.
• Exploration of the role of theragnostic imaging in predicting and measuring radiation absorbed doses.
• Analysis of the challenges and requirements for implementing personalized dosimetry.

Main Results:

• Empirical dosing has led to suboptimal radiation absorbed doses in some patients, limiting treatment efficacy.
• Accurate prediction and measurement of radiation absorbed doses enable personalized treatment.
• Individualized treatment planning offers the prospect of improved clinical outcomes in molecular radiotherapy.

Conclusions:

• Personalized dosimetry, enabled by theragnostic imaging, is crucial for optimizing molecular radiotherapy outcomes.
• Implementing accurate dosimetry requires significant investment and a change in clinical practice.
• Further clinical studies are needed to validate the benefits of individualized treatment planning against its costs.